NASDAQ · Biotechnology

Tenaya Therapeutics, Inc. (TNYA) Stock

$0.58 +7.13% NASDAQ: TNYA Healthcare

Valuation

MetricValue
Price$0.58
Market Cap$126.51M
P/E Ratio-1.06
P/B Ratio1.77
P/S Ratio91.69
EPS (TTM)$-0.59
52-Week High$2.35
52-Week Low$0.53
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-108.05%
ROA-110.24%
ROCE-142.06%
Gross Margin1.45%
Operating Margin-381.59%
Net Margin-368.91%
Debt/Equity0.06
Current Ratio7.07

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-73.0M$-126.0M$-131.0M$-116.0M$-93.0M
Net Profit$-73.0M$-124.0M$-124.0M$-111.0M$-91.0M
EPS$-1.69$-2.76$-1.68$-1.31$-0.59
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$317.0M$279.0M$171.0M$120.0M$147.0M
Total Liabilities$38.0M$36.0M$31.0M$27.0M$24.0M
Cash$38.0M$95.0M$46.0M$4.0M$101.0M
Borrowings$16.0M$15.0M$12.0M$14.0M$11.0M

Latest News

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire · Jul 15, 2026 Tenaya Therapeutics Names Eric Hyllengren CFO MT Newswires · Jun 29, 2026 Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer GlobeNewswire · Jun 29, 2026 Exploring 3 High Growth Tech Stocks in US Market Simply Wall St. · Jun 15, 2026 Exploring High Growth Tech Stocks In The US Market Simply Wall St. · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-61.0M$-104.0M$-102.0M$-91.0M$-68.0M
Investing Cash Flow$-264.0M$63.0M$47.0M$0$55.0M
Financing Cash Flow$0$0$0$1.0M$0
Net Cash Flow$-90.0M$57.0M$-49.0M$-42.0M$96.0M
Free Cash Flow$-86.0M$-125.0M$-103.0M$-92.0M$-69.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-0.50
FCF Yield-58.68%
Quick Ratio4.52
Interest Coverage0.00
Return 1Y21.66%
Return 3Y-84.24%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABEOAbeona Therapeutics Inc. $4.97 +0.10% -4.43 $282.98M 0.00%
CRBUCaribou Biosciences, Inc. $0.48 -0.52% -1.13 $47.48M 0.00%
ENTAEnanta Pharmaceuticals, Inc. $12.50 +3.31% -5.32 $363.48M 0.00%
FHTXFoghorn Therapeutics Inc. $2.00 +0.50% -2.11 $117.43M 0.00%
HUMAHumacyte, Inc. $0.41 -9.35% -1.00 $68.09M 0.00%

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. is led by CEO Faraz Ali, employs 97 people, headquartered in US, publicly traded since 2021.

Tenaya Therapeutics, Inc. (TNYA) stock trades at $0.58 with a market capitalization of $126.51M. The stock is valued at a price-to-earnings (P/E) ratio of -1.06, price-to-book of 1.77, price-to-sales of 91.69. Over the past 52 weeks the stock has ranged between $0.53 and $2.35, and currently trades 75.3% below its 52-week high.

On profitability, Tenaya Therapeutics, Inc. generates a return on equity (ROE) of -108.05%, return on capital employed of -142.06%, an operating margin of -381.59%, a net profit margin of -368.91%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides